Oral olanzapine disposition in adolescents with schizophrenia or bipolar I disorder: A population pharmacokinetic model

Pediatric Drugs

Volumn 12, Issue 3, 2010, Pages 201-211

  Lobo, Evelyn D ^a   Robertson Plouch, Carol ^a   Quinlan, Tonya ^a   Hong, Quan ^a   Bergstrom, Richard F ^b  

^a ELI LILLY AND COMPANY   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

Bipolar I disorders; Olanzapine; Pharmacokinetics; Schizophrenia; Treatment

Indexed keywords

CLOZAPINE; OLANZAPINE;

ADOLESCENT; ARTICLE; BIPOLAR I DISORDER; BLOOD SAMPLING; BODY WEIGHT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFECT; ELECTROCHEMISTRY; FEMALE; GROUPS BY AGE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MONTE CARLO METHOD; MULTICENTER STUDY; PREDICTOR VARIABLE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SCHIZOPHRENIA; SEX DIFFERENCE; STEADY STATE;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; FEMALE; HUMANS; MALE; MODELS, BIOLOGICAL; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; SEX CHARACTERISTICS;

EID: 77952570424     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.2165/11532580-000000000-00000     Document Type: Article

References (26)

1. Carlson GA, Naz B, Bromet EJ. The phenomenology of assessment of adolescent- onset psychosis: observation from a first-admission psychoses project. In: Findling RL, Schulz SC, editors. Juvenile-onset schizophrenia: assessment, neurobiology, and treatment. Baltimore (MD): The Johns Hopkins University Press, 2005: 1-38
2. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995; 21 (3): 419-429
3. Beasley Jr CM, Sanger T, Satterlee W, et al. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl) 1996 Mar; 124 (1-2): 159-167
4. Tohen M, Zarate Jr CJ, Sanger TM.Aplacebo-controlled trial of olanzapine in psychotic or non-psychotic acute mania. Schizophr Res 1998; 29: 1-2
5. Patel BR, Kurtz DL, Callaghan JT, et al. Effects of smoking and gender on population pharmacokinetics of olanzapine (OL) in a phase III clinical trial. Pharm Res 1996; 13: S407-8
6. Zypreza (olanzapine) [package insert]. Indianapolis (IN): Eli Lilly and Company, 2008 [online].Available fromURL: http://pi.lilly.com/us/zyprexa-pi. pdf [Accessed 2010 Jan 29]
7. Tohen M, Kryzhanovskaya L, Carlson G, et al. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry 2007 Oct; 164: 1547-1556
8. Kryzhanovskaya L, Schulz SC,McDougle C, et al. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2009 Jan; 48 (1): 60-70
9. Theisen FM, Grabarkiewicz J, Fegbeutel C, et al. Olanzapine overdose in children and adolescents: two case reports and a review of the literature. J Child Adolesc Psychopharmacol 2005 Dec; 15 (6): 986-995
10. Grothe DR, Calis KA, Jacobsen L, et al. Olanzapine pharmacokinetics in pediatric and adolescent inpatients with childhood-onset schizophrenia. J Clin Psychopharmacol 2000 Apr; 20 (2): 220-225
11. Data on file, Eli Lilly and Company, 2006
12. Dittmann RW, Meyer E, Freisleder FJ et al. Effectiveness and tolerability of olanzapine in the treatment of adolescents with schizophrenia and related psychotic disorders: results from a large, prospective, open-label study. J Child Adolesc Psychopharmacol 2008 Feb; 18 (1): 54-69
13. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed, text revision. Washington, DC: American Psychiatric Association, 2000
14. Kaufman J, Birmaher B, Brent D, et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 1997 Jul; 36 (7): 980-988
15. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed, revised. Washington, DC: American Psychiatric Association, 1987
16. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
17. Sheiner LB, Hashimoto Y, Beal SL. A simulation study comparing designs for dose ranging. Stat Med 1991 Mar; 10 (3): 303-321
18. Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic- pharmacodynamic models: I. Models for covariate effects. J Pharmacokinet Biopharm 1992 Oct; 20 (5): 511-528
19. Powers JD. Statistical considerations in pharmacokinetic study design. Clin Pharmacokinet 1993 May; 24 (5): 380-387
20. Bergstrom RF, Callaghan JT, Cerimele BJ, et al. Population pharmacokinetics and plasma concentrations of olanzapine. In: Tran PV, Bymaster FP, Tye N, et al., editors. Olanzapine (Zyprexa): a novel antipsychotic. Philadelphia (PA): Lippincott, Williams, and Wilkins, 2000: 232-252
21. Callaghan JT, Bergstrom RF, Ptak LR, et al. Olanzapine: pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 1999 Sep; 37 (3): 177-193
22. Zyprexa [package insert]. Indianapolis (IN): Eli Lilly and Company, 2008
23. Relling MV, Lin JS, Ayers GD, et al. Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. Clin Pharmacol Ther 1992 Dec; 52 (6): 643-658
24. Schweikl H, Taylor JA, Kitareewan S, et al. Expression of CYP1A1 and CYP1A2 genes in human liver. Pharmacogenetics 1993 Oct; 3 (5): 239-249
25. Usall J, Suarez D, Haro JM, et al. Gender differences in response to antipyschotic treatment in outpatients with schizophrenia. Psychiatry Res 2007 Dec; 153 (3): 225-231
26. Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology: drug disposition, action, and therapy in infants and children.NEngl J Med 2003 Sep; 349 (12): 1157-1167